Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 12/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 11/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 11/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 11/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 11/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 11/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21109182 | 0.83 | NR2E1 (0.38) | NR2E1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1616168 | 0.80 | ALDH1A1 (0.49) | NR2E1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL10153280 | 0.79 | PDE3B (0.34) | — | |
| SCHEMBL7733899 | 0.78 | ALDH1A1 (0.39) | NR2E1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9868208 | 0.78 | EGLN2 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL10153120 | 0.78 | ALDH1A1 (0.49) | — | |
| SCHEMBL21109184 | 0.78 | NR2E1 (0.40) | NR2E1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1616782 | 0.77 | PSEN1 (0.45) | NR2E1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1616928 | 0.77 | NR2E1 (0.46) | NR2E1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7935796 | 0.77 | TSHR (0.43) | NR2E1PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772504-B2 | Substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120022090-A1 | NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022090-A1 | NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | NR2E1 804/4885PSEN1 4/4885PSEN2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.